DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
Pullin Dennis W reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Dennis W. Pullin received a grant of 332 shares of common stock. The award was recorded at a price of $0.00 per share, indicating it was compensation rather than a market purchase. Following this grant, he directly holds 2,421 DaVita common shares.
Hollar Jason M. reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Jason M. Hollar received a grant of 332 shares of common stock. The award was recorded at a price of $0.00 per share as a compensation-related grant or award. Following this transaction, he directly owns a total of 6,355 DaVita common shares.
BERRY CHRISTOPHER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. Chief Accounting Officer Christopher Michael Berry reported receiving a grant of 3,649 shares of Common Stock as a compensation-related award, recorded at $0.00 per share rather than an open-market purchase.
According to the footnote, these are restricted stock units scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to the applicable award terms. After this award, Berry directly holds 19,640 shares of DaVita common stock.
DaVita Inc. CFO and Treasurer Joel Ackerman reported routine equity compensation and related tax-withholding transactions. He received a grant of 15,427 Stock Appreciation Rights tied to common stock at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to award terms. He also acquired 5,706 shares of common stock as a stock award, with related restricted stock units vesting 50% on the same future dates. To cover tax obligations from the vesting of prior performance stock units and restricted stock units, 42,820 shares of common stock were withheld rather than sold in the open market, through three F-code transactions at a reference price of $150.72 per share. After these awards and tax withholdings, Ackerman directly holds 183,905 shares of DaVita common stock, reflecting ongoing equity-based compensation and associated tax settlements rather than discretionary open-market trades.
DaVita Inc. director Adam H. Schechter received a grant of 332 shares of common stock on March 15, 2026, as a non-cash award. The shares were acquired at a stated price of $0.00 per share and increased his directly held position to 5,442 shares of DaVita common stock.
Moore Gregory J. reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Gregory J. Moore received an equity award of 332 shares of Common Stock on March 15, 2026. The shares were granted at no cash cost per share, indicating a compensation-related award rather than an open-market purchase. Following this grant, Moore directly holds 7,563 DaVita shares.
DaVita Inc. Chief Legal & Public Affairs Officer Kathleen Alyce Waters reported equity compensation grants and related tax withholdings. She received 8,610 stock appreciation rights tied to an equal number of common shares at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to award terms. She also acquired 3,185 restricted stock units that are scheduled to vest on the same dates.
To cover tax obligations from the vesting of previously granted performance stock units and restricted stock units, 33,863 shares of common stock were withheld at $150.72 per share through several F-code transactions. Following these compensation-related grants and withholdings, Waters directly holds 124,599 shares of DaVita common stock.
DaVita Inc.’s Chief Compliance Officer, James O. Hearty, reported equity compensation and related tax withholding transactions. He received a grant of 3,050 stock appreciation rights tied to Common Stock at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030.
He also acquired 1,128 shares of Common Stock as a share-based award, with the related restricted stock units scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030. In separate transactions, a total of 11,578 shares of Common Stock were withheld at $150.72 per share to satisfy tax withholding obligations upon vesting of performance stock units and earlier restricted stock units. After these compensation and tax-withholding entries, Hearty directly holds 38,137 shares of DaVita Common Stock.
DaVita Inc. director Wendy Lee Schoppert received a compensation-related stock award. On March 15, 2026, she acquired 332 shares of DaVita common stock with no purchase price, reported as a grant or similar award. Following this award, she directly held 332 shares and indirectly held 3,305 shares through the Wendy L. Schoppert Revocable Trust.
HEARTY JAMES O reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. reported that Chief Compliance Officer James O. Hearty received two non-derivative grants of common stock on March 10, 2026, comprising 1,756 shares and 20,533 shares, delivered upon satisfaction of criteria for earlier performance stock unit awards granted in 2022 and 2023 that are scheduled to vest 100% on March 15, 2026.
After these awards, he directly holds 48,587 shares of DaVita common stock.